SEC annual filings · CSTL

How much revenue does Castle Biosciences Inc report?

Castle Biosciences Inc reported revenue of $344.2 million for the fiscal year ended , up 3.7% from the year before.

Castle Biosciences Inc: revenue at each fiscal year end

Fiscal years ended to As filed with the SEC

Castle Biosciences Inc: revenue at each fiscal year end (31 December 2017 to 31 December 2025)

Each point is the revenue of one fiscal year as the company filed it. Pointing at the chart shows the fiscal year end and the revenue. Every measure is under "The numbers behind the chart".

The lineLatest:

  • Revenue, year ended 31 December 2025$344M

Observed .

RankingOurs

In 2025 it ranked 2,456th of 3,061 by revenue, 2,230th of 2,827 by profit, and 2,563rd of 3,059 by total assets.

The ranking counts the companies with a figure in that year, among the companies of the set that have had revenue of 100 million dollars or more in the SEC data we read, the largest first. Equal figures share a rank.

See every measure by year

Record yearOurs

Its revenue in 2025, $344.2 million, is the highest of the years shown.

Its profit was highest in 2024, $18.2 million; in 2025 it was −$24.2 million.

See every year

The company

The SEC lists its industry as Services-Medical Laboratories, in the group health services.

Its fiscal year ends on 31 December, as the SEC lists it. Listed as CSTL (Nasdaq).

See the companies in health services

As filed

Facts as filed with the SEC, and our arithmetic on them. Not investment advice.

The balances are those the SEC data holds for the fiscal year end.

Understanding the figures of Castle Biosciences Inc

Where it stands today

Castle Biosciences Inc reported revenue of $344.2 million for the fiscal year ended 31 December 2025.

Where do these numbers come from?

Public companies file annual reports with the SEC, and the figures in them are tagged so that a computer can read them. This page shows those figures as the company filed them, year by year.

Read more

A year is named for the year the SEC data files it under. For a fiscal year ending from January to May that is the year before the one it ends in; for one ending in late June it can be either. The fiscal year end is shown over each column of the table.

The numbers behind the chart

What did Castle Biosciences Inc report in each year?9 years, newest first
Castle Biosciences Inc: measures by year as filed, newest year first (dollars; shares as a count)
Measure202520242023202220212020201920182017
Fiscal year ended
Revenue$344M$332M$220M$137M$94.1M$62.6M$51.9M$22.8M–
Profit or loss−$24.2M$18.2M−$57.5M−$67.1M−$31.3M−$10.3M$5.28M−$6.37M–
Total assets$579M$531M$453M$447M$463M$439M$120M$22.4M–
Equity$471M$456M$391M$399M$412M$416M$85.1M−$56.6M−$50.3M
Cash$117M$120M$98.8M$123M$330M$410M$98.8M$4.48M–
Long-term debt$10.1M$10.0M$0.00M––$0.00M$26.7M$24.5M–
Cash from operations$64.3M$64.9M−$5.63M−$41.7M−$19.0M$9.87M$7.01M−$12.3M–
Capital spending$36.0M$28.3M$13.6M$5.63M$3.48M$4.75M$0.94M$0.28M–
Research spending$51.9M$52.0M$53.6M$44.9M$29.6M$13.3M$7.38M$4.85M–
Income tax paid$1.60M$2.50M$0.20M$0.12M$0.02M$0.10M−$0.15M$0.16M–
Public float, as filed$576M$587M$311M$472M$1.50B$519M$0.00M––

The table scrolls sideways; the first column stays in place.

What do these figures leave out, and how are they cited?Limits, dates and how to cite

What this number cannot tell you

  • Figures are as the company filed them, in dollars. A year the company restated shows the restated figure.
  • A balance (total assets, equity, cash, long-term debt) is shown under a year only when the SEC data dates it within ten days of the fiscal year end. Shares outstanding and public float are the figures on the cover page of the annual report, shown only on the dates a cover gives them: shares up to ninety days after the year end, public float from ninety to two hundred and sixty days before it (the end of the second fiscal quarter). A figure of a period (profit, cash from operations, capital spending, research spending, income tax paid, buybacks, dividends) is shown under a year only when the SEC data ends that period within sixty days of the fiscal year end.
  • Capital spending is the cash the company paid for property, plant and equipment in its fiscal year, a line of its cash flow statement. The SEC data holds the line under two names, "payments to acquire property, plant and equipment" and "payments to acquire productive assets". Each year is read under one of the two names, and the two are never added.
  • A dash is a gap: the company did not report that figure for that year. The dash says which when it is pointed at.
  • The SEC labels its annual figures by calendar year, so a fifty-two or fifty-three week year that ends in late June can share its label with its neighbour, and a fiscal year can be missing from the table. No comparison is made across such a gap: a record, a highest since or a change from the year before is not said between two years whose ends are more than four hundred days apart.
  • Revenue is the company's total revenue as it files it. A bank or lender that files no other revenue line can show its interest income.
  • A company that files together with a parent or a subsidiary shows only its own figures, so the same business can have two pages.
  • Public float is the figure the company states on its cover page for the shares held by outside investors. It is the company's statement, not a price set on an exchange.
  • The companies under "Largest in" are the ones with the most revenue in the year of the ranking among the companies of the same SEC industry code (or, where the line says the group, of the same industry group) in the set, those that have had revenue of 100 million dollars or more in the SEC data we read. A company the set does not hold is not in it. The SEC assigns the industry code.

Observed .

How to cite this

U.S. Securities and Exchange Commission, company filings (XBRL data from data.sec.gov), filings of Castle Biosciences Inc, through the fiscal year ended 31 December 2025. Compiled by 500metrics, "How much revenue does Castle Biosciences Inc report?", https://500metrics.com/companies/castle-biosciences.

Can the data be downloaded?companies-castle-biosciences.csv

Download every year as CSV: 9 rows, to , 1,141 bytes.

Our text and compilation: CC BY 4.0.

Executive payAs filed

For the fiscal year ended , the SEC publishes a total pay of $6.8 million and pay actually paid of $13.2 million for the principal executive officer of Castle Biosciences Inc.

Its total pay for the fiscal year ended ($6.8 million) ranked 461st of 892 companies on this site with a total pay figure for 2025.

Pay of the principal executive officer, as the SEC publishes it, one value per year. Total pay is the officer's total in the company's summary compensation table. Stock and option awards count at their value on the day they were granted. One award can cover several years, so a year with a large award is not a year of cash pay.

Pay actually paid is not the cash the person received. It adds the rise or fall in the value of stock and options already held, so it can be negative. If a company named two executives in a year, the figure may cover one of them or be missing.

The year at the head of a column is the SEC's label for a fiscal year; the fiscal year end of each is in the first row.

Castle Biosciences Inc: pay of the principal executive officer by year, newest year first (dollars as filed)
Figure20252024202320222021
Fiscal year ended
Total pay$6.79M$6.94M$1.61M$7.55M$6.52M
Pay actually paid$13.2M$9.97M$779,818$3.08M$2.13M

The table scrolls sideways; the first column stays in place.

See the companies ranked by pay

Insider purchases and salesAs filed

In the filings from to , insiders of Castle Biosciences Inc reported no purchases (code P) and 220 sales (code S) worth $19.1 million.

Insiders are the officers and directors of a company and the owners of more than ten percent of its shares. A purchase (code P) is an open market or private purchase and a sale (code S) an open market or private sale. Grants, awards, exercises of options, gifts and shares withheld for tax have other codes and are not counted.

Only the first Form 4 of a trade counts: an amended report, an initial statement of holdings and an annual statement are not read. The value of a line is its shares times its price per share, in dollars. A line with no price, or a price of zero, counts in the counts and not in the dollar sums. So does a line whose value is over two billion dollars: it is left out of the sums and of the largest lists by rule, because values this large are mostly entry errors in the report.

Facts as filed with the SEC, and our arithmetic on them. A purchase or a sale says what an insider did, not why. Not investment advice. The first insider a report names is shown, and how many others it names.

Castle Biosciences Inc: the newest 20 purchases and sales (codes P and S) reported on Form 4, the newest trade first
TradedInsiderRelationshipTradeSharesPriceValue
Juvenal Tobin WChief Commercial OfficerSale (code S)3,195$35.07$0.11M
Juvenal Tobin WChief Commercial OfficerSale (code S)2,828$35.044$0.10M
Juvenal Tobin WChief Commercial OfficerSale (code S)3,288$32.67$0.11M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)325$36.814$0.01M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)382$36.814$0.01M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)1,025$36.814$0.04M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)2,393$36.005$0.09M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)2,816$36.005$0.10M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)7,555$36.005$0.27M
Juvenal Tobin WChief Commercial OfficerSale (code S)5,341$36.619$0.20M
Show 10 more rows
Castle Biosciences Inc: the newest 20 purchases and sales (codes P and S) reported on Form 4, the newest trade first (continued)
TradedInsiderRelationshipTradeSharesPriceValue
Juvenal Tobin WChief Commercial OfficerSale (code S)1,237$35.577$0.04M
Juvenal Tobin WChief Commercial OfficerSale (code S)3,288$33.08$0.11M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)2,718$31.91$0.09M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)3,198$31.91$0.10M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)8,580$31.91$0.27M
Juvenal Tobin WChief Commercial OfficerSale (code S)3,288$33.64$0.11M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)2,718$35.566$0.10M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)3,198$35.566$0.11M
MAETZOLD DEREK JDirector, Pres. & Chief Exec. OfficerSale (code S)8,580$35.566$0.31M
Oelschlager Kristen MChief Operating OfficerSale (code S)1,346$36.38$0.05M

The table scrolls sideways; the first column stays in place.

See the insider trades of every company, month by month

Money managersAs filed

For the quarter ended 30 June 2026, 177 managers reported a holding of Castle Biosciences Inc on Form 13F, worth $624.81 million as filed.

For the quarter ended 31 March 2026, 187 managers reported $655.12 million, so the number of managers is −10 and the value −$30.3M since then.

Money managers file a report on Form 13F every quarter, within 45 days after it ends, listing the securities they hold and the value of each on the last day of the quarter. Values are as filed, in dollars. A manager that reports more than one class of the company's common stock is counted in each class, so managers are not added across classes. A holding that two managers both report counts twice in a value.

The reports name an issuer and a class, not a company in the SEC's company files, so a holding is matched to this company by its name, for ordinary and common shares. A holding written under another spelling of the name is not counted.

Castle Biosciences Inc: managers that reported a holding on Form 13F, by class of common stock (dollars as filed)
ClassManagers, 30 June 2026Value reported, 30 June 2026Managers, 31 March 2026Value reported, 31 March 2026
COM177$625M187$655M

The table scrolls sideways; the first column stays in place.

See the largest money managers

Page updated